financetom
Business
financetom
/
Business
/
Sequans Shares Jump 35% After $384M Debt-Equity Raise to Fund Bitcoin Treasury
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sequans Shares Jump 35% After $384M Debt-Equity Raise to Fund Bitcoin Treasury
Jul 8, 2025 9:58 AM

Sequans Communications’ (SQNS) surged more than 40% after the wireless-chip designer closed a $384 million private placement with plans to spend the bulk of that in bitcoin (BTC).

The deal combined a $195 million sale of American depositary shares (ADS) and warrants at $1.40 with $189 million of five-year secured convertible debentures priced at a 4% discount, according to a press release.

The France-based company's ADSs rose to $2.01 on Nasdaq after the announcement.

Investors can convert at $2.10 per American depositary share and, if all warrants are exercised, Sequans could net another $57.6 million, with the funds also being earmarked for bitcoin purchases.

CEO Georges Karam said the company sees the asset enhancing its financial resilience and creating long-term value. Sequans designs low-power 4G and 5G modems used in smart meters, asset trackers and industrial sensors.

Swan Bitcoin will source and custody the coins while Northland Capital Markets and B. Riley Securities handled the financing.

The move sees Sequans join a growing list of publicly traded firms adopting bitcoin as their primary treasury reserve asset. A total of 852,309 BTC are currently held by these firms, according to Bitcointreasuries data.

The bulk of those coins are held by Strategy (MSTR), which has 597,325 BTC on its balance sheet. It’s followed by MARA Holdings ( MARA ) with 50,000 BTC and XXI, with 37,230 BTC.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI and Bain are extending their partnership to sell OpenAI's ChatGPT and other AI tools to the consulting firm's clients, The Wall Street Journal reported Thursday. The companies started a sales partnership in 2023 and in August 13,000 Bain consultants got licenses for ChatGPT Enterprise, according to the...
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Oct 17, 2024
02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Oct 17, 2024
09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases. The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now...
Copyright 2023-2026 - www.financetom.com All Rights Reserved